NCT02313077View on ClinicalTrials.gov

A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

December 17, 2014

Primary Completion Date

April 17, 2015

Study Completion Date

March 15, 2016

Conditions
Healthy
Interventions
BIOLOGICAL

MVA-BN-filo

One 0.5 mL intramuscular (IM) injection of 1E8 (50%Tissue Culture Infectious Dose \[TCID50\]) on Day 1 (Groups 1 and 2), or on Day 29 (Group 3), or on Day 57 (Group 4), or on Day 15 (Group 5).

BIOLOGICAL

Ad26. ZEBOV

One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1 (Groups 3, 4 and 5), or on Day 29 (Group 1), or on Day 57 (Group 2).

OTHER

Placebo

One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 (Groups 1 and 3), or on Day 1 and 57 (Groups 2 and 4).

Trial Locations (1)

Unknown

Oxford

All Listed Sponsors
lead

Crucell Holland BV

INDUSTRY

NCT02313077 - A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants | Biotech Hunter | Biotech Hunter